Dr. Mudussara Asad Khan, MD

Dr. Khan practices at AdventHealth Daytona Beach in Daytona Beach, Florida, part of AdventHealth.

Dr. Khan's NPI, 1821290362, was assigned on June 5, 2007. Dr. Khan graduated from West Virginia University School Of Medicine in 2002. Dr. Khan holds Florida license ME114473.

Dr. Khan's primary practice is AdventHealth Daytona Beach, at 301 Memorial Medical Parkway, Daytona Beach, FL 32117 in Volusia County. The practice phone is (386) 231-6000.

Dr. Khan's primary practice is AdventHealth Daytona Beach in Daytona Beach, Florida, part of AdventHealth. Dr. Khan is also affiliated with AdventHealth Palm Coast. The medical group on file is Florida Cancer Specialists & Research Institute. Dmand AI also links Dr. Khan to 2 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Khan practices, 5 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Khan's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Khan is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Khan's licenses on file in 3 states: Florida, West Virginia and Pennsylvania.

Dmand AI lists breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT), fluid and electrolyte imbalances and immune deficiency disease among the conditions Dr. Khan treats.

CMS data shows 48,506 Medicare services from Dr. Khan across 43 procedure codes in 2024, for 596 Medicare patients. Medicare paid $583,156 for them.

CMS counts 596 Medicare patients who saw Dr. Khan in 2024. The largest group is 65 to 74, with 246 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.12, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Khan's median patient age at 68, with 62% women.

In 2024, Dr. Khan wrote 1,436 Medicare Part D claims for 292 patients. 72% of them were for generic drugs. CMS names the drug for 1,062 of them, across 33 drugs with 11 or more claims each, at $2,382,661 in total drug cost. In 2023, CMS named 981 claims across 32 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Khan for performance year 2024, reported as part of a group. Dr. Khan accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 2 papers to Dr. Khan in 2010. Dr. Khan's most frequent co-authors are Ramin Altaha, MD and Govardhanan Nagaiah, MD.

Dmand AI links Dr. Khan to 3 clinical trials, 2 of them phase 3 studies. 2 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Neoplasms, Male and Carcinoma, Intraductal, Noninfiltrating.

CMS Open Payments shows 1,080 general payments to Dr. Khan from 87 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 91% of the total. Novartis Pharmaceuticals Corporation paid the most, $1,925.

Dr. Khan graduated from West Virginia University School Of Medicine in 2002.

Dr. Khan is in network with 20 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. PPO plans come from the most carriers, 13. Check the plan with the practice before a visit.